Simple blood test could spot colon cancer early

NCT ID NCT07168876

Recruiting now Diagnosis Sponsor: Epiliquid Holding, Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study is testing a new blood test called Delta-HLD to see how well it can detect colorectal cancer in average-risk people aged 45-75. About 3,200 participants will give a blood sample before their scheduled screening colonoscopy, which will be used as the gold standard for comparison. The goal is to see if this liquid biopsy can accurately identify cancer and advanced precancerous growths.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Delta-HLD liquid biopsy test
What this could lead to: If successful, this could provide a simpler, less invasive blood test for colorectal cancer screening, potentially increasing screening rates.
What could go wrong: This is an early validation study, not a treatment trial. The test may not be accurate enough to replace colonoscopy, and results may not apply to higher-risk groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER (CRC)

Contacts and locations

Locations

Epiliquid
RECRUITING

Mendoza, Mendoza Province, 5500, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.